Replies to post #428393 on Elite Pharmaceuticals Inc (ELTP)

[Just give me $1.50]

Why didn't you listen to the last CC?

We made MORE profits on LESS revenue because of Vyvanse:

Profits: $12.5 million revenues in January > $14.4 million ENTIRE third quarter revenues

Nasrat: "The profits made in the month of January were more than the profits made in the ENTIRE third quarter."

I'm guessing gross margins on Vyvanse will be much better too

[WhenMoon]

True, however the assumption that Vyvanse market will get cut in half is way too pessimistic. Generic market share is currently sitting at around 75% so the most the IQVIA annual sales could even possibly decrease from future generic entry is around 25%, and even that would be if there was 0% branded market share. Given this I think mrwn2010's number's are feasible if not conservative. Reason being, that while the IQVIA annual sale numbers are not a 1 for 1 conversion in terms of potential revenue for Elite, due to the reasons you stated, the total IQVIA market should be estimated to be around 3.5 billion or even higher, not 2 billion, when factoring in decreases for generic entry.
My opinion.

[mrwrn2010]

Bleh, good point. Keep forgetting it's not a 1:1. 

Hopefully as Moon said, the market size doesn't shrink as much as expected plus this is *only* Vyvanse we're talking about. Says nothing about future (Concerta?) products currently in the pipeline. 

We are in a good place, IMO. Small for sure but Methadone launch should also be soon.